Medtron AG, based in Saarbrücken, is a specialized developer and manufacturer of injectors for computed tomography, magnetic resonance imaging, and angiography. The company also distributes consumables for these medical devices to hospitals, clinics, and radiological practices worldwide. In 2025, the company founded the 100% subsidiary Medtron International GmbH to further strengthen its international presence. Medtron AG is characterized by its independence from contrast media manufacturers and continuously invests in research and development as well as the optimization of its supply chains.
Die Entwicklung und die Fertigung von medizinischen Geräten und der Handel mit diesen Geräten, soweit er nicht genehmigungspflichtig ist.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Saarbrücken Local Court, HRB 13752 (as of 1 November 2026)
| Name | Type | City |
|---|---|---|
| Markus Bappert | Vorstand | Kleinblittersdorf |
Source: German Commercial Register (Handelsregister) Saarbrücken Local Court, HRB 13752 (as of 1 November 2026)
| Date | Event Type | Event |
|---|---|---|
| 13.05.2022 | Satzung amended | Satzung |
| 24.08.2017 | Satzung amended | Satzung |
| 07.11.2014 | Satzung amended | Satzung |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 28.10.2003 | Share Capital Set | — | 50.000 € |
| Date | Contract | Value |
|---|---|---|
| 7.1.2026 | Supplier · Vivantes - Netzwerk für Gesundheit GmbH | — |
Source: German Commercial Register (Handelsregister) Saarbrücken Local Court, HRB 13752 (as of 1 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | Rohergebnis€23.8M2 | €1,560,394 | €26,510,157 | — |
| 2024 | Rohergebnis€23.7M2 | €1,765,885 | €25,322,146 | — |
| 2023 | Rohergebnis€23.8M2 | €1,092,588 | €26,103,092 | — |
| 2022 | Rohergebnis€22.5M2 | €930,549 | €27,206,230 | — |
| 2021 | Rohergebnis€21.6M2 | €2,224,244 | €25,397,989 | — |
| 2020 | Rohergebnis€20.7M2 | €3,040,833 | €19,879,066 | — |
| 2019 | Rohergebnis€20.1M2 | €2,746,771 | €18,489,364 | — |
| 2018 | Rohergebnis€19M2 | €2,905,271 | €18,945,535 | — |
| 2017 | Rohergebnis€16.9M2 | €2,617,126 | €16,552,414 | — |
| 2016 | Rohergebnis€14.7M2 | €2,310,727 | €13,248,429 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Saarbrücken Local Court, HRB 13752 (as of 1 November 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €12,912,798 | 93.4% |
| Depreciation | €592,124 | 4.3% |
| Interest & Similar | €322,155 | 2.3% |
